Anavex Life Sciences Corp. is advancing a potential breakthrough for patients with rare genetic conditions through its latest intellectual property milestone. The company recently secured U.S. Patent No. 12558340, titled ‘ANAVEX2-73 for the treatment of genetic neurodevelopmental disorders’, which focuses on its lead drug candidate, blarcamesine. This innovation targets the root causes of complex diseases like Rett syndrome, providing a new path for pediatric and adult care.
Targeting the Sigma-1 Receptor
The patented technology utilizes a small-molecule activator to restore cellular balance within the central nervous system. By targeting the sigma-1 receptor, the treatment helps the body manage protein folding and reduce cellular stress. This mechanism is vital for maintaining healthy nerve cells and preventing the toxic build-up of proteins. Unlike traditional therapies that only mask symptoms, this approach seeks to stabilize the basic biological functions of the brain.
Impact on Rare Genetic Disorders
The patent specifically addresses conditions linked to MeCP2 gene mutations, which often lead to severe impairments in movement, breathing, and communication. This new legal protection covers various administration methods, including oral and transdermal options. This flexibility is essential for patients who may struggle with standard pill-based medications. The invention marks a major step forward in precision medicine for underserved patient populations.
Future of Neurodevelopmental Care
With this patent, the company strengthens its position in the R&D landscape for neurodegenerative and neurodevelopmental health. The move ensures long-term development of therapies that could eventually treat autism, cerebral palsy, and Angelman syndrome. By securing these claims, the research team can focus on clinical trials that bring these life-changing treatments to market. This progress offers renewed hope for families navigating the challenges of rare genetic disorders.
Learn More:
Are you developing new or improved products, or thinking of applying for a patent? Did you know your research work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? To find out more, please check out our free online eligibility test.
Feel free to book a quick teleconference with one of R&D Tax specialists if you would like to learn more about R&D Tax Credit opportunities.
Who We Are:
Swanson Reed is one of the largest Specialist R&D Tax Credit advisory firm in the United States. With offices nationwide, we are one of the only firms globally to exclusively provide R&D Tax Credit consulting services to our clients. We have been exclusively providing R&D Tax Credit claim preparation and audit compliance solutions for over 30 years.
Swanson Reed’s New York office provides R&D tax credit consulting and advisory services to New York City, Buffalo, Rochester, Yonkers, Syracuse, Albany, New Rochelle, Mount Vernon, Schenectady, Utica, White Plains, Troy, Niagara Falls, Binghamton, Rome, Long Beach, Poughkeepsie, North Tonawanda, Jamestown, and Ithaca.
Swanson Reed hosts daily free webinars and provides free IRS CE and CPE credits for CPAs. For more information please click here or contact your usual Swanson Reed representative.
Are you eligible?
Why choose us?
Pass an Audit?
What is the R&D Tax Credit?
The Research & Experimentation Tax Credit (or R&D Tax Credit), is a general business tax credit under Internal Revenue Code section 41 for companies that incur research and development (R&D) costs in the United States. The credits are a tax incentive for performing qualified research in the United States, resulting in a credit to a tax return. For the first three years of R&D claims, 6% of the total qualified research expenses (QRE) form the gross credit. In the 4th year of claims and beyond, a base amount is calculated, and an adjusted expense line is multiplied times 14%. Click here to learn more.
Never miss a deadline again
Stay up to date on IRS processes
Discover R&D in your industry
R&D Tax Credit Preparation Services
Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.
If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.
R&D Tax Credit Audit Advisory Services
creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.
Our Fees
Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/
Choose your state
